Advanced Filters
noise

amyloidosis Clinical Trials

A listing of amyloidosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 161 clinical trials
T Thomas Treibel, MBBS PhD

Aortic Stenosis and Cardiac Amyloidosis

The dual pathology of aortic stenosis (AS) and cardiac amyloidosis (CA) is increasingly recognized. Even tough efforts have been undertaken to bring cohorts together, the largest cohort of AS-ATTR to date is <50 patients. It is the aim of the present international, multi-center registry to collect ~300 patients with AS-CA …

18 years of age All Phase N/A
L Lou LG GRANGEON, Doctor

Phenotypic and Molecular Characterisation of Cerebral Amyloid Angiopathy

Cerebral Aβ amyloid angiopathy is a severe disease characterised by amyloid deposits in the cerebral vessels, manifested mainly by recurrent cerebral haematomas and cognitive impairment. Diagnostic criteria are based on brain imaging, but the usefulness of this imaging in predicting the course of the disease remains undetermined. The genetic component …

18 - 99 years of age All Phase N/A
L Lilia Zakhama, Prof

Cardiac Amyloidosis in HFpEF Tunisian Patients

Cardiac amyloidosis (CA) has recently been reported as a common cause of heart failure with preserved left ventricular ejection fraction (HFpEF), with a prevalence of 6% in elderly HFpEF patients. However, the diagnosis of CA is still challenging and requires multiple costly investigations. Regardless of the type of CA, TTR …

60 - 90 years of age All Phase N/A
K Kathy Brown

Intracardiac Flow Assessment in Cardiac Amyloidosis

The primary objective of this study is to define the intracardiac flow imaging biomarkers in cardiac amyloidosis.

40 years of age All Phase N/A
R Riemer Slart, Prof MD PhD

Quantitative-imaging in Cardiac Transthyretin Amyloidosis

Transthyretin amyloid cardiomyopathy (ATTR-CM), is a heart muscle disease that's stops the heart muscle working properly. With an ageing population, it is increasingly common but untreated, it has a poor prognosis. Several novel expensive treatments have become available, although we do not understand exactly how they work and why some …

40 years of age All Phase N/A
D David Kersting, MD PhD

Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease

This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend …

18 years of age All Phase N/A

Cardiac Amyloidosis Registry of University Hospital Leipzig

This is a clinical registry of patients with cardiac amyloidosis being treated at University Hospital Leipzig. The aim of the registry is to collect detailed information about clinical events, symptoms, imaging, biomarkers, comorbidities, and treatment from routine patient management which would not be provided by randomized clinical trails.

years of age All Phase N/A
J Jørn A Lillebø, MD

ATTR Cardiac Amyloidosis in a Selected Population

Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy will be examined to decide wether they have cardiac amyloidosis. All patients with positive biopsy will be followed closely for 10 years wit echocardiography an clinically.

50 years of age All Phase N/A
K Kelley Jackson

Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.

18 years of age All Phase N/A
S Stephen Helmke

Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers

Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine substitution at position 122 (V122I) in the transthyretin (TTR) protein. Virtually exclusive to Blacks, this is the most common cause of hereditary cardiac amyloidosis (hATTR-CA) worldwide. hATTR-CA leads to worsening heart failure (HF) …

30 - 80 years of age All Phase N/A

Simplify language using AI